Good afternoon. Thank you, Angela. And welcome to our Q4 full fiscal year 2019 earnings call. I’m Marc Hedrick, President and CEO of Plus Therapeutics. And joining me is our new Chief Financial Officer, Mr. Andrew Sims. First, on behalf of the entire Plus Therapeutics team, I wish all of you the best possible health during these incredible times. We are a company dedicated to healthcare, and we hope you and your families are coping as well as you can. And we do encourage you to follow the advice of your doctors and public health officials in this turbulent time. Today, though, I'm pleased to report the results of Plus Therapeutics fourth quarter and full fiscal year 2019. However, before we go through a review of last fiscal year, let's first focus on more current news, and in particular, our exciting announcement this morning. Most importantly, today, we announced that we have entered into a definitive agreement to license multiple rare cancer drug product candidates from private Texas-based biotechnology company, NanoTx Therapeutics. The transaction terms include an upfront payment of $400,000 in cash and $300,000 in Plus stock. Furthermore, the company may pay up to $136.5 million in development and sales milestone payments and a tiered single-digit royalty on U.S. and European sales. The transaction, subject to customary closing conditions, is expected to close in the second quarter of fiscal 2020. The licensed drug portfolio is anchored up nanoliposome-encapsulated radionuclides and related technologies for a number of cancer targets. The lead drug asset is a chelated Rhenium NanoLiposome, also called, RNLTM, initially being developed for recurrent glioblastoma. RNL is infused directly into the brain tumor via precision brain mapping and convection enhanced delivery technology to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following initial surgical resection and treatment with chemotherapy and radiation. We are very excited about this transaction. It is consistent in all ways with our publicly stated strategic aims that have been mentioned frequently in the past few quarters. Among those aims, strategic expansion of our pipeline and in this case doing exclusive in-licensing transaction, also cost efficient development via a more virtual drug development model by leveraging non-diluted sources of funding, in this case, technology with a strong funding track record via the state of Texas and the NIH and National Cancer Institute, and a clinical focus in oncology and more rare poorly met indications, in this case, such as glioblastoma, carcinomatosis, and others, and then finally, leveraging our extensive expertise and novel drug formulation, in nanoliposomes, in this case by applying our internal capabilities on CMC, a clinical development to move these products into late stage trials, and one day potentially commercial introduction. Also, as we noted previously in our plan, we prefer to invest in drug candidates that meet three key criteria: First, they address an unmet or substantially underserved medical need; Second, they combine known active pharmaceutical ingredients that have extensive safety and efficacy information with new technologies that improve both safety and efficacy; and third, these products will have at least a $250 million addressable market. These drug candidates evolved in this transaction check all three boxes. I'll provide more details on the technology and the clinical status regarding this transaction momentarily. But in summary, this transaction comports precisely with our previous guidance. And we are particularly pleased that we were able to deliver our first deal so promptly within the first quarter of our new fiscal year. So, now, before getting to our FYI 2019 review, I'd like to address the current global crisis now in everyone's mind, specifically COVID-19 and this Company's response to it. I am relieved to report that there's been no material impact on our operations as a result of the coronavirus. None of our employees have tested positive, and we currently expect no material impact on our results for fiscal year 2020, which ends December 31, 2020. Our recent implementation of a substantially virtual development model is serving us well during the pandemic. Additionally, our facilities in Austin and San Antonio remain open, although while lightly staffed, we have flexible work schedules to provide maximum support for our employees. Be sure our company has business continuity plans at all sites, should the need arise to implement them. No supply chain interruptions have occurred and we remain in close coordination with our partners and employees of potential risks and mitigations. We are also exploring the provisions of the recently passed CARES law as to how it might provide support to Plus. As a final point with regard to this issue, besides protecting our workforce and maintaining our business, we are also trying to make a difference to others coping with the impact of the coronavirus. Recently, we donated a lion's share of our personal protective equipment inventory such as surgical masks, gloves and other protective items to San Diego Scripps Health for distribution to its frontline doctors, nurses, and other healthcare practitioners that are on the front lines caring for patients affected by the COVID-19 pandemic. As many of you know, Scripps Health is a private nonprofit integrated health system in San Diego and Plus Therapeutics of course has had a longtime presence in San Diego and La Jolla. We'll continue to do our part to look after our employees and look for other ways we can help the communities in which we live and work. Okay. So, let's return to the FY 2019 review, which marked the productive and pivotal time in the history of this Company. In fact, Q4 was the first full quarter of the new revitalized Plus Therapeutics, a clinical stage pharmaceutical company focused on the discovery, development and delivery of complex and innovative treatments for patients battling rare cancers. Let me briefly summarize some of the substantial progress we made in 2019. Most notably, we injected $26 million into the balance sheet by a combination of transactions including selling noncore assets, completing a $15 million public offering and negotiating a $4.6 million study closeout reimbursement from the U.S. Department of Health and Human Services. Also, in order to preserve cash and ensure efficient future capital deployments, we consolidated operations from La Jolla, California to Texas and significantly virtualized our development model, meaning an increase in cost effective reliance on trusted consultants and less on expensive fulltime infrastructure. In short, we slimmed down to a built for scale engine of drug development, monetization and liquidity. Our move to Texas was a key part of this. We are in close geographic proximity to some of the world's most renowned cancer researchers and institutions. As you probably know, our new home state of Texas has a statewide commitment to oncology, best characterized by the Cancer Prevention and Research Institute of Texas, whose funding is second globally only to the United States federal government in the public funding of cancer research. Founded in ‘08, CPRIT has since awarded almost $2.5 billion towards over 1,500 grants focused on academic research, cancer prevention, and product development research. To summarize all this, I'll just reiterate what I said in our recent letter to shareholders. I believe strongly that Plus Therapeutics now has the financial capability, development focus and cost structure to achieve long-term viability and growth. Now, let me march ahead here and provide further details on the transaction we announced this morning. We've licensed a family of drug candidates characterized by novel chemistry, specifically, the BMEDA-chelated. BMEDA is a chelator, in this chelates rhenium-186. These are radio isotopes encapsulated via nanoliposomes. These unique drugs are both beta and gamma energy emitters. That two third serves to both kill [Technical Difficulty], which is very important, particularly in the brain. And these precise formulations [Technical Difficulty] one to two millimeter radioactive penetration and a 90-hour half life. When delivered directly to tumors, these compounds can deliver approximately 30x or 30-fold the radiation to tumors than can standard external beam radiation without also local side effect incurred being a radiation, which is aimed through normal tissue to get to the brain. Furthermore, [Technical Difficulty] various modalities [Technical Difficulty] the newly licensed [Technical Difficulty] multi-institutional consortium based in Texas at the [Technical Difficulty] center and [Technical Difficulty] MD Anderson Cancer Center and it was led by the internationally renowned, Dr. Andrew Brenner, MD, PhD. The lead drug assets in this basket of [Technical Difficulty], is rhenium nanoliposome developed initially for recurrent glioblastoma. Dr. Brenner and his [Technical Difficulty] even today, in the modern times that we live in, radiation is the most effective component of the standard multimodal therapeutic regime used in glioblastoma. Multiple randomized studies show about a five-month improvement in survival with external beam radiation alone compared to the additional 2.5 months with the addition of chemotherapy and three months for targeted tumor treating fields. By infusing the drug directly into the tumor, bypassing the blood brain barrier, normal brain external tissues are [Technical Difficulty] In the case of these drugs, the mechanism of action is clear cut. We know radiation is effective against glioblastoma if an adequate dose can be effectively delivered. For comparison, it’s very important. [Technical Difficulty] patient protocols for recurrent glioblastoma, typically [Technical Difficulty] the radiation dose is measured. In contrast, the most recent patient dosed with RNL in the clinical trial that's ongoing today received over 500 gray -- 35 to 500 gray. In terms of clinical status with respect to this trial, we are currently in a U.S. FDA approved Phase 1 dose finding study at a single site in Texas in San Antonio with plans underway to expand to two additional sites in Texas at UT Southwestern Medical School and MD Anderson. In the trial thus far 13 patients have been dosed to date and we are now in the fifth dosing cohort. The radiation dose in the current cohort is now approximately at 15 times the dose that is typically delivered by external beam radiation. Higher doses are planned in subsequent cohorts. Thus far, no serious adverse events have been observed in the trial. And in terms of efficacy signals, we continue to follow these patients but the first two patients in which complete tumor coverage with RNL was achieved, survived for 30 and 33 months respectively. And that's compared to a median survival of about nine months in patients who received standard of care. Another thing we really like about this technology is it has had substantial third-party review and support. It was previously funded by the cancer prevention and research Institute of Texas, and there may be further opportunities for [Technical Difficulty] as well. Currently the technology is funded through Phase 2. It’s in Phase 1 but through Phase 2 by the National Institutes of Health and National Cancer Institute here in the U.S. The recently awarded $3 million grant award from the NCI and NIH will function primarily to create cost offsets for Plus during the continued clinical development of RNL for recurrent glioblastoma. So, what about next steps? [Technical Difficulty] simultaneously, namely complete the Phase 1 trial and determine the maximum tolerated dose, explore ways to accelerate development, both internally and with the FDA if supported by the clinical data, finalize our plans for more definitive safety and efficacy studies with the agency, and complete the CMC and scalability work required to move this to late stage clinical and commercial product availability. Another reason our team is so enthusiastic about this technology and this transaction is that this same product candidate is in preclinical development for several additional indications, including breast, head & neck, leptomeningeal carcinomatosis, liver and ovarian cancers, and appears to be quite promising in those, although still early. This technology could be a game-changer for some of these really tough clinical problems. Therefore, it's [Technical Difficulty] continue to refine the development plan and support development for additional indications and report back as soon as we complete that planning and process. Furthermore, another licensed preclinical product candidate as part of this transaction is a co-encapsulated doxorubicin and chelated rhenium nanoliposome that has been studied in the treatment of squamous cell carcinoma of the head and neck and may have used in a number of other tumors as well. Finally, these assets are supported by numerous patents worldwide in peer reviewed publications. So, let me move on to the rest of our pipeline. As you may know, our pipeline also contains DocePLUS, which is a Phase 2 ready albumin stabilized PEGylated liposomal docetaxel that is intended to target a number of cancers including small cell lung cancer. To summarize what we've said before, it's a reformulation of Sanofi’s TAXOTERE or docetaxel, using our proprietary nanotechnology platform, being developed for relapsed small cell lung cancer as a new and alternative treatment option to Novartis’ HYCAMTIN or topotecan. According to Decision Resources, topotecan is a standard of care in this patient population and generated $190 million in sales in 2018. DocePLUS has an FDA orphan designation for small cell lung cancer, and we have received FDA pre-IND feedback indicating that the product may be eligible for the 505(b)(2) regulatory pathway. Prior to today's announced transaction, management's plan had been to proceed to a Phase 2 trial of small cell lung cancer patients with platinum sensitive disease who have progressed after first line therapy. However, management believe prudence dictates that in the current macroeconomic environment, the uncertainty about the capital markets and with multiple new assets in the pipeline, we will proactively in Q2 adjust as needed our clinical priorities and plans for capital deployment. We'll do that in such a way to maximize stockholder return. We’ve therefore put a near-term temporary hold on development spend for DocePLUS, while we rapidly assess the overall situation. Regarding our other asset, DoxoPLUS, we're in discussions with interested parties in acquiring this drug potential as the potential first generic version of CAELYX in Europe. Additionally, we continue to review a number of other co-development and in-licensing opportunities geared to expand our pipeline. And now, I'll turn it over to Andrew Sims, our newly arrived Chief Financial Officer, for a financial review. But, before I do, Andrew, let me just give you a brief word about Andrew's background who’s a great addition to the team. Andrew was previously an audit partner at Mazars, a global accounting advisory, audit, tax and consulting firm. He was originally based in both the Oxford, England and New York offices. Andrew audited and advised global public clients, including a variety of health care companies, primarily based in Europe, and he was the lead partner on over 50 acquisitions and numerous cross border financings and other transactions. He's a Certified Public Accountant here in the U.S., and a Chartered Accountant in England and Wales. And he was raised and educated in the United Kingdom, but he still has an understandable accent. So, Andrew, we welcome you aboard and turn it over to you.
